In a press release, POM states, withdrawal of drugs containing sibutramine be conducted from 14 October. This is a follow-up of the information security aspects of drug product obtained by the study results "Sibutramine on Cardiovascular Outcomes Triaf" (SCOUT), which showed an increased risk of cardiovascular events.
"With this latest information security aspects, in order to protect the safety and public health, POM RI has conducted the cancellation and withdrawal of marketing authorization of drug products containing sibutramine starting on 14 October," said Chief BPOM Kustantinah.
Read more »
No comments:
Post a Comment